NCT02719574 · MORE INFO

Limitations, agreements, and source contact

Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation · Source last updated 2026-06-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

other Details: At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

point Of Contact

email: clinicaltrials@novonordisk.com
organization: Novo Nordisk A/S
phone: (+1) 866-867-7178
title: Clinical Reporting Anchor and Disclosure (1452)

Complete source fields

certain Agreement

other Details: At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

point Of Contact

email: clinicaltrials@novonordisk.com
organization: Novo Nordisk A/S
phone: (+1) 866-867-7178
title: Clinical Reporting Anchor and Disclosure (1452)

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice